Abstract

A novel series of zileuton-hydroxycinnamic acid hybrids were synthesized and screened as 5-lipoxygenase (5-LO) inhibitors in stimulated HEK293 cells and polymorphonuclear leukocytes (PMNL). Zileuton’s (1) benzo[b]thiophene and hydroxyurea subunits combined with hydroxycinnamic acid esters’ ester linkage and phenolic acid moieties were investigated. Compound 28, bearing zileuton’s (1) benzo[b]thiophene and sinapic acid phenethyl ester’s (2) α,β-unsaturated phenolic acid moiety 28, was shown to be equipotent to zileuton (1), the only clinically approved 5-LO inhibitor, in stimulated HEK293 cells. Compound 28 was three times as active as zileuton (1) for the inhibition of 5-LO in PMNL. Compound 37, bearing the same sinapic acid (3,5-dimethoxy-4-hydroxy substitution) moiety as 28, combined with zileuton’s (1) hydroxyurea subunit was inactive. This result shows that the zileuton’s (1) benzo[b]thiophene moiety is essential for the inhibition of 5-LO product biosynthesis with our hydrids. Unlike zileuton (1), Compound 28 formed two π–π interactions with Phe177 and Phe421 as predicted when docked into 5-LO. Compound 28 was the only docked ligand that showed a π–π interaction with Phe177 which may play a part in product specificity as reported.

Highlights

  • In addition to playing a protective role in response to adverse stimuli, inflammation is potentially harmful in many chronic diseases when excessive [1]

  • We have recently demonstrated acid phenethyl washave morerecently potent than zileuton

  • (1) benzo[b]thiophene moiety is essential for the inhibition of 5-LO product biosynthesis with our hydrids

Read more

Summary

Introduction

In addition to playing a protective role in response to adverse stimuli, inflammation is potentially harmful in many chronic diseases when excessive [1]. By converting arachidonic acid (AA) to leukotrienes (LTs), which are potent lipid mediators [2], 5-Lipoxygenase (5-LO, EC1.13.11.34) is a key enzyme in the inflammatory cascade [3,4]. LTs are known to play an important role in the development and regulation of the inflammatory response [5]. LTs are involved in many diseases such as psoriasis [5,6], asthma [7], allergic rhinitis [8], atherosclerosis [9], Alzheimer’s disease [10], and various cancers [11,12,13]. Many efforts have been made to develop anti-leukotriene drugs, given the involvement of these mediators in many pathologies. Approved by the FDA in 1996, zileuton ((Zyflo® ) (1); Figure 1)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call